[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. - Wikidata - wikimedia - TriplyDB

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

http://www.wikidata.org/entity/Q44359133

about

Imaging radiation response in tumor and normal tissue.Imaging tumour hypoxia with positron emission tomography Positron emission tomography to assess hypoxia and perfusion in lung cancer Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats.18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions Pharmacokinetic Analysis of Dynamic 18F-Fluoromisonidazole PET Data in Non-Small Cell Lung Cancer.A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma Development of a nomogram combining clinical staging with (18)F-FDG PET/CT image features in non-small-cell lung cancer stage I-III Recent Trends in PET Image Interpretations Using Volumetric and Texture-based Quantification Methods in Nuclear Oncology.Molecular mechanisms of hypoxia in cancer.PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence Molecular imaging of metastatic potential.Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET Combining targeted agents with modern radiotherapy in soft tissue sarcomas.A phase Ib/II translational study of sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.Positron emission tomography imaging of cancer biology: current status and future prospects Assessing tumor hypoxia by positron emission tomography with Cu-ATSM RETRACTED: PET imaging of tumour hypoxia.Imaging oxygenation of human tumours.Performance of Positron Emission Tomography and Positron Emission Tomography/Computed Tomography Using Fluorine-18-Fluorodeoxyglucose for the Diagnosis, Staging, and Recurrence Assessment of Bone Sarcoma: A Systematic Review and Meta-Analysis.Targeting tumor perfusion and oxygenation to improve the outcome of anticancer therapy.Correlation of PET images of metabolism, proliferation and hypoxia to characterize tumor phenotype in patients with cancer of the oropharynx Positron emission tomography: clinical applications in oncology. Part 2.Hypoxia imaging-directed radiation treatment planning.Targeted molecular imaging in oncology: focus on radiation therapy.Epigenetic re-expression of HIF-2α suppresses soft tissue sarcoma growth Biological characteristics of intratumoral [F-18]‑fluoromisonidazole distribution in a rodent model of glioma.Overview of early response assessment in lymphoma with FDG-PET.Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.Quantitative multimodality imaging in cancer research and therapy Novel imaging approaches to head and neck cancer The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck.Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.Imaging of tumor glucose utilization with positron emission tomography.A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapy.Molecular imaging of hypoxia with radiolabelled agents

P2860

Q26798266-F325F630-75C6-4C3F-83E6-72222C90546D Q26851422-E9FF1C8B-082C-4171-9DFD-1300661673F1 Q27026940-42106FBE-0C2B-416B-B3ED-730E7CF94C7F Q28078116-576A4B35-C288-4B2B-8F8B-22C87F525994 Q30559873-9C9130AD-F72E-4CCC-B22F-FCFD88F03FA0 Q30660095-AE1F3753-675E-4B25-97DC-3DAD75C37197 Q31165401-306BF320-6006-46B8-A82B-DE5C6A10CE79 Q33395573-A0AB0F0B-90C9-464A-9552-B74222282CEB Q33417472-3A4E5C96-1E8D-4EC4-B757-209F6315C49F Q33617538-14279A8A-4A0C-4EA4-A625-1E4AF8F9F60B Q33669828-DEB3BF02-0F38-42AA-AB10-A9921AE52848 Q33705108-836D95B5-424A-468B-BB0D-BC3E1B4363A6 Q33818999-8DCD6959-0BE2-464F-B569-46D348625D0F Q33917943-4C377EB1-BED7-4F4D-82B0-60994642502E Q34235986-66FC20AE-B304-4F8A-85B2-3189EA767B47 Q34396047-D2BAF1F6-29F2-4434-8F52-0E9D1344A6BA Q34687036-9C3CB8D8-CD37-41B1-BE16-315C828137DE Q34697688-0BCDC1A5-CC34-48FD-B9AD-430B4D0A7639 Q35565683-603D7512-74ED-4855-8F4D-BDA27073E604 Q35650691-F5069F31-9F8D-43B3-9C2E-B27EE955A74F Q35676947-7C1BD051-D8ED-402D-80C5-95A41C0B911C Q35769381-9A3C2833-07B4-4DD5-B49D-80FD26659148 Q35975832-3EEF30E2-68DD-4768-AB4F-1A6AD51A18B4 Q36387970-91104AFE-1E39-4487-944B-A0A69D693C53 Q36448703-D8B00E82-02CC-45CE-9265-C03AB640B772 Q36501278-6509A4B2-2075-4832-9632-E94D6BEAC7F5 Q36528175-4E58A9C8-9D56-4B33-BDAB-E6F91B8C48F5 Q36548712-46B2DBF2-F597-4A0B-85CC-0EEDC60DF212 Q36684412-2D0F2F8B-A958-472D-A1E8-2FABC26FDCD1 Q36927213-B90CB0D3-8613-4F5D-BD7E-54654DF240F6 Q36940477-0A86CF5C-ABDE-44C5-A336-3BE6DBED0771 Q37007810-82A25236-D998-41E3-BE20-E7934AEBE076 Q37012938-EE7962E7-305D-4F23-A03B-079A928C2627 Q37035291-3169E206-5680-4FAD-B5C5-11757398829A Q37093034-672CBC52-47D2-462C-9DE0-248D8C64665E Q37140172-3478B306-1991-4C1D-8170-61DDCF9E5875 Q37140996-9D896546-52D7-4872-88E9-08329EF03F74 Q37181778-B52A7F8A-5074-48CE-A95C-5033A2B150E3 Q37297234-7DE867E8-BB5E-4DCE-8A62-C99EA2F96206 Q37378239-1E6C020C-6B41-4FE8-82A9-31658E20AA53

P2860

[(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.

http://www.wikidata.org/entity/Q44359133

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@en

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@nl

type

label

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@en

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@nl

prefLabel

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@en

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@nl

P1433

Q44359133-9F38BF14-623E-4B16-B7CC-478C4FFFD946

P1476

Q44359133-E12B2BD4-834A-40CB-A44F-A0EF257450A7

P2093

Q44359133-07E033D4-7E43-42F7-BD7E-FF3043EF2D88

Q44359133-113F8CCE-9DF5-4372-9440-283BD1E6A1E6

Q44359133-20E19D8E-0941-43BE-87E9-79409FCA216A

Q44359133-3750DD5F-E0F7-4DE4-A970-6EEA6ADEAAD0

Q44359133-61B3EA89-E191-49E3-B503-FFC44839224B

Q44359133-63901FEF-7254-4BE2-BBF6-45702368BC96

Q44359133-6E61FC62-8087-4113-96F1-5E43BEF8BF68

Q44359133-771B0571-612B-47E4-92E1-4F003A17BEF2

Q44359133-91B75C57-C3F4-48AF-96BB-A8B2DDAE6B06

Q44359133-B41EA941-F0E8-486E-816E-B044DC1DF062

P2888

Q44359133-8555D8BB-6F98-4277-96D2-D6423D3438F8

P304

Q44359133-A3DDCF56-8981-4702-9E23-2BC05714B4DD

P31

Q44359133-E976028E-497D-46F4-934A-687FD48E56AA

P356

Q44359133-E0FF311A-CDA6-402D-9A42-5E0B9277B607

P433

Q44359133-21756C9B-0B59-4D4F-ADA0-F540B21D46A4

P478

Q44359133-5D4F6AE0-308D-4741-B3F0-3780333FC5C8

P577

Q44359133-3827A896-1A51-44F3-B446-25935FADB6EE

P698

Q44359133-E6E2D52A-679F-4510-9DF4-6E67982D4E4A

P921

Q44359133-90BF871C-5A0F-4FD6-96A7-52D75F0C5590

P356

S00259-002-1096-7

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

[(18)F]FMISO and [(18)F]FDG PE ...... etabolism and VEGF expression.

@en

P2093

D C Wilson

http://www.w3.org/2001/XMLSchema#string

E U Conrad

http://www.w3.org/2001/XMLSchema#string

J D Bruckner

http://www.w3.org/2001/XMLSchema#string

J F Eary

http://www.w3.org/2001/XMLSchema#string

J G Rajendran

http://www.w3.org/2001/XMLSchema#string

J R Grierson

http://www.w3.org/2001/XMLSchema#string

J S Rasey

http://www.w3.org/2001/XMLSchema#string

K A Krohn

http://www.w3.org/2001/XMLSchema#string

L K Chin

http://www.w3.org/2001/XMLSchema#string

L M Peterson

http://www.w3.org/2001/XMLSchema#string

P2888

s00259-002-1096-7

P304

695-704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-002-1096-7

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P577

2003-03-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12632200

http://www.w3.org/2001/XMLSchema#string

P921